HC Wainwright Begins Coverage on Sintx Technologies (NASDAQ:SINT)

Stock analysts at HC Wainwright began coverage on shares of Sintx Technologies (NASDAQ:SINT) in a research note issued on Monday,Benzinga reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 273.13% from the stock’s current price.

A number of other research firms have also recently commented on SINT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sintx Technologies in a research note on Thursday, January 22nd. Ascendiant Capital Markets lowered their target price on Sintx Technologies from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $11.00.

Sintx Technologies Stock Performance

NASDAQ:SINT opened at $2.68 on Monday. The company has a market capitalization of $11.04 million, a PE ratio of -0.47 and a beta of 0.66. The company has a 50 day simple moving average of $2.78 and a two-hundred day simple moving average of $3.38. Sintx Technologies has a fifty-two week low of $1.71 and a fifty-two week high of $6.78.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in shares of Sintx Technologies by 53.4% during the fourth quarter. Geode Capital Management LLC now owns 26,624 shares of the company’s stock worth $103,000 after purchasing an additional 9,265 shares in the last quarter. Virtus Wealth Solutions LLC purchased a new position in shares of Sintx Technologies during the third quarter worth about $388,000. Finally, Veracity Capital LLC grew its holdings in shares of Sintx Technologies by 10.3% during the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after purchasing an additional 7,464 shares in the last quarter. Hedge funds and other institutional investors own 18.38% of the company’s stock.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.